Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: A day after shares spiked on a promising earnings report, Chinese online retailer Vipshop Holding (NYSE:VIPS) fell as much as 16% today, on concerns about new leadership in China.
So what: Vipshop gained 10% yesterday, after it reported revenue growth of 197% and its first quarterly profit at $0.01 a share. Analysts were expecting a $0.07 loss. Today, a host of Chinese stocks fell, and the Shanghai Composite was down 1.2% as the new leadership under Xi Jinping is unlikely to pull out the same stimulus measures that the former administration used to increase expansion. China's GDP is expected to grow by 7.7% this year, its slowest rate since 1999.
Now what: Today was the second straight drop of 1% or more in the Shanghai index, so the pullback in Vipshop shares is likely coming from that macro news and the exaggerated bump yesterday. Since the early morning lows, shares have bounced back to close out the day with just a 7% loss. Considering the company hit breakeven in its latest report, and is sporting a phenomenal growth rate, I would take today's drop as a buying opportunity. A few more quarters like this one, and shares should surely move higher.
Stay up to date with VIPshop.
- Add Vipshop Holdings to your Watchlist
Jeremy Bowman has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why the Apple Inc. iPhone X Isn't Doing as Well as Hoped in China
The answer might surprise you.
3 Signs You're Better Off Delaying Retirement
If you're coping with any of the issues below, then retiring now is probably a bad idea.
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Which stock wins in a head-to-head match-up between the big biotech and the big pharma company?